Info all Articles

On Friday, September 7 at 8 pm ET, celebrities and musicians will come together to build awareness for cancer and raise money for cancer research through the Stand Up 2 Cancer (SU2C) telethon.

100 percent of all public donations from the special will go to cancer research.

Watch the Stand Up 2 Cancer Special

The Stand Up to Cancer Special airs Friday, September 7 from 8 to 9 pm ET.

The Stand Up to Cancer Special will air on all major networks without commercial interruption. Networks include ABC, NBC, CBS as well as BIO, E!, HBO, MLB Network, Palladia, Showtime TBS, VH1 and STARZ.

About Stand Up 2 Cancer

Founded in 2008, SU2C has raised more than $180 million for innovative cancer research. Since its inception, SU2C has made grants to seven multi-disciplinary “Dream Teams” of researchers as well as to 26 young innovative scientists who are undertaking potentially high-reward projects to end the reign of cancer as a leading cause of death in the world today.

Eighty-five institutions are currently involved, including Penn Medicine’s Abramson Cancer Center.

The Penn Medicine SU2C Dream Team

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.

The SU2C Dream Team at Penn is actively researching better ways to prevent, diagnose and treat pancreatic cancer. Together, members of the Pancreatic Cancer Dream Team working to translate scientific breakthroughs into new treatment options faster than ever before. Their research focuses on developing tests using advanced imaging technology to understand pancreatic cancer cells and developing new, personalized pancreatic cancer treatments based on their research.

Members of the Pancreatic Cancer SU2C Dream Team at Penn Medicine

Pancreatic cancer researchers at Penn Medicine are at the forefront of developing new, personalized approaches to pancreatic cancer treatment.

These Penn clinicians and researchers are part of the SU2C Pancreatic Cancer Dream Team.

Chi Van Dang, MD, PhD
Professor of Medicine, Hematology/Oncology
Director, Abramson Cancer Center
Director, Abramson Family Cancer Research Institute

Jeffrey A. Drebin, MD, PhD, FACS
John Rhea Barton Professor of Surgery
Chairman, Department of Surgery

Hank Kung, PhD
Professor of Radiology and Pharmacology
Department of Radiology
Perelman School of Medicine

Peter J. O’Dwyer, MBBCh, MD
Professor of Medicine, Hematology/Oncology
Perelman School of Medicine

Watch Stand Up 2 Cancer and Join the Conversation

Watch Stand Up to Cancer on Friday, September 7 at 8 pm ET, and join Penn Medicine on Twitter as we discuss pancreatic cancer and its treatment at Penn Medicine, and how researchers and clinicians on the SU2C Pancreatic Cancer Dream Team are changing the way cancer is treated today.

Tonight, celebrities, and musicians will come together to build awareness for cancer and raise money for cancer research through the Stand Up to Cancer (SU2C) telethon. 100 percent of all public donations from the special will go to cancer research.

Watch the Stand Up 2 Cancer Special

The Stand Up 2 Cancer Special airs TONIGHT from 8 to 9 pm ET.

The SU2C Special will air on all major networks without commercial interruption. Networks include ABC, NBC, CBS as well as BIO, E!, HBO, MLB Network, Palladia, Showtime TBS, VH1 and STARZ.

About SU2C

Founded in 2008, SU2C has raised more than $180 million for innovative cancer research. Since its inception, SU2C has made grants to seven multi-disciplinary “Dream Teams” of researchers as well as to 26 young innovative scientists who are undertaking high-risk, potentially high-reward projects to end the reign of cancer as a leading cause of death in the world today.

Eighty-five institutions are currently involved, including Penn Medicine’s Abramson Cancer Center.

Watch SU2C and Join the Conversation

Watch Stand Up to Cancer on Friday, September 7 at 8 pm ET, and join Penn Medicine on Twitter as we discuss pancreatic cancer and its treatment at Penn Medicine, and how researchers and clinicians on the SU2C Pancreatic Cancer Dream Team are changing the way cancer is treated today.

Each year, more than 1.2 million new patients are diagnosed with cancer every year in the United States.

To help combat this, Stand Up 2 Cancer brings together dream teams of the best and the brightest researchers spanning disciplines, institutions, countries and specialties, to join in a unified fight against cancer with translational research.

By providing these teams with long term funding, groups of scientists from peer institutions get to work collaboratively, rather than competitively, to develop new treatments quickly.

Transforming Pancreatic Cancer to a Treatable Disease

Over the next three years, the newly announced SU2C-Lustgarten Foundation Pancreatic Cancer Convergence dream team hopes to apply advances in immunotherapy (hardwiring the body's immune system to fend off cancer as opposed to more traditional treatment options) to the realm of pancreatic cancer.

Co-leading the effort is Penn Medicine’s own director of Translational Research, Robert Vonderheide, MD, DPhil.

Why Pancreatic Cancer?

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly. Despite recent advancements, survival rates remain poor, as more than 90 percent of pancreatic cancer patients die within the first year of diagnosis, creating an urgent need for new treatments.

Why Immunotherapy?

Clinical efforts focused specifically on pancreatic cancer have failed to improve the survivability or quality of life for those affected. In short, greater research and better answers must be created or found, through novel approaches like immunotherapy.

Today, those diagnosed with the cancer, their caretakers and loved ones face a grim prognosis. To help alleviate this need in the pancreatic cancer community, Stand Up 2 Cancer is bringing together researchers, scientists, and doctors from institutions across the country to work together.

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.

As featured in Time Magazine, Penn Medicine’s Dr. Jeffery Drebin and the Stand Up 2 Cancer Pancreatic Dream Team is answering that call. Their team-based multi-disciplinary approach is translating scientific breakthroughs into new treatment options faster than ever before.

Dr. Drebin and the pancreatic cancer dream team is focused on developing tests using advanced imaging technology to understand pancreatic cancer cells and developing new, personalized pancreatic cancer treatments based on their research.

About Pancreatic Cancer

Pancreatic cancer is cancer that develops within the pancreas, the gland about six inches long that is responsible for making hormones, including the enzymes responsible for the digestion of food and control of blood sugar.

Pancreatic cancer develops when cells within the pancreas begin to grow out of control. It may spread, or metastasize, to nearby lymph nodes and organs such as the liver and lungs.

About Pancreatic Cancer Treatment at Penn Medicine

At Penn Medicine, patients with pancreatic cancer receive their care from a multidisciplinary team of nationally recognized experts in the diagnosis, treatment and research of gastrointestinal cancer.

Penn Medicine's multidisciplinary approach to cancer diagnosis and treatment provides better outcomes and gives patients access to the most advanced treatment, surgical techniques and clinical trials.

Learn more about pancreatic cancer treatment at Penn.

On Friday, September 7 at 8 pm ET, celebrities and musicians will come together to build awareness for cancer and raise money for cancer research through the Stand Up 2 Cancer (SU2C) telethon.

100 percent of all public donations from the special will go to cancer research.

 

 

Watch the Stand Up 2 Cancer Special

The Stand Up 2 Cancer Special airs Friday, September 7 from 8 to 9 pm ET.

Stand Up 2 Cancer will air on all major networks without commercial interruption. Networks include ABC, NBC, CBS as well as BIO, E!, HBO, MLB Network, Palladia, Showtime TBS, VH1 and STARZ.

About Stand Up 2 Cancer

Founded in 2008, SU2C has raised more than $180 million for innovative cancer research. Since its inception, SU2C has made grants to seven multi-disciplinary “Dream Teams” of researchers as well as to 26 young innovative scientists who are undertaking potentially high-reward projects to end the reign of cancer as a leading cause of death in the world today.

Eighty-five institutions are currently involved, including Penn Medicine’s Abramson Cancer Center.

The Penn Medicine SU2C Dream Team

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.

The SU2C Dream Team at Penn is actively researching better ways to prevent, diagnose and treat pancreatic cancer. Together, members of the Pancreatic Cancer Dream Team working to translate scientific breakthroughs into new treatment options faster than ever before. Their research focuses on developing tests using advanced imaging technology to understand pancreatic cancer cells and developing new, personalized pancreatic cancer treatments based on their research.

Members of the Pancreatic Cancer SU2C Dream Team at Penn Medicine

Pancreatic cancer researchers at Penn Medicine are at the forefront of developing new, personalized approaches to pancreatic cancer treatment.

These Penn clinicians and researchers are part of the SU2C Pancreatic Cancer Dream Team.

Chi Van Dang, MD, PhD
Professor of Medicine, Hematology/Oncology
Director, Abramson Cancer Center
Director, Abramson Family Cancer Research Institute

Jeffrey A. Drebin, MD, PhD, FACS
John Rhea Barton Professor of Surgery
Chairman, Department of Surgery

Hank Kung, PhD
Professor of Radiology and Pharmacology
Department of Radiology
Perelman School of Medicine

Peter J. O’Dwyer, MBBCh, MD
Professor of Medicine, Hematology/Oncology
Perelman School of Medicine

Watch Stand Up 2 Cancer and Join the Conversation

Watch Stand Up 2 Cancer Friday, September 7 at 8 pm ET.

November is National Pancreatic Cancer Awareness Month. Pancreatic cancer remains the fourth leading cause of cancer death in the United States.

1. Pancreatic cancer is cancer that develops within the pancreas, the gland about six inches long that is responsible for making hormones, including the enzymes responsible for the digestion of food and control of blood sugar.
2. Pancreatic cancer survival rates are poor as more than 90 percent of pancreatic cancer patients die within the first year of diagnosis. Recent advancements in pancreatic cancer research have had little impact patients' pancreatic cancer prognosis, and new pancreatic cancer treatments are desperately needed.
3. It's estimated that more than 37,000 people died from pancreatic cancer last year, and another 44,000 will be diagnosed with pancreatic cancer this year.
4. Risk factors for pancreatic cancer include smoking, having diabetes, being obese, being over the age of 65, having chronic inflammation of the pancreas, or a family history of pancreatic cancer.
5. Penn's pancreatic cancer team is nationally recognized for its specialized techniques in treating pancreatic cancer, and is part of the multidisciplinary team of cancer specialists at the Abramson Cancer Center.
6. Pancreas surgery is technically difficult, and surgeons at Penn Medicine perform the highest volume of pancreatic procedures, including the Whipple surgery (procedure), in the Philadelphia region, and are among the top 10 in the United States.
7. There are currently multiple active clinical trials for pancreatic cancer at Penn, two of which are related to the Stand Up 2 Cancer effort. Penn and its fellow pancreatic cancer dream team sites have recruited more than 1,000 patients for these studies thus far, while only a few thousand patients enroll in pancreatic cancer clinical trials in the Unites States every year.
8. The Stand Up To Cancer (SU2C or Stand Up 2 Cancer) Dream Team at Penn Medicine supports and contributes to pancreatic cancer research.
9. Members of the Stand Up 2 Cancer Dream Team for pancreatic cancer research at Penn are developing tests using advanced imaging technology to understand pancreatic cancer cells and develop new, personalized pancreatic cancer treatments based on their pancreatic cancer research.
10.  Penn Medicine's Abramson Cancer Center is one of seven sites coordinating "Dream Teams" and the only site coordinating projects focusing on pancreatic cancer.

Learn more about pancreatic cancer and pancreatic cancer research at Penn Medicine through Stand Up 2 Cancer. 

2012 was an exciting year for the Abramson Cancer Center. We are featuring blogs featured on the Focus On Cancer blog that highlight cancer treatment breakthroughs, coping tips and ideas, education and inspiration. Today, we are highlighting the partnership between the Stand Up 2 Cancer Foundation and Penn Medicine.

The SU2C Dream Team at Penn is actively researching better ways to prevent, diagnose and treat pancreatic cancer. Together, members of the Pancreatic Cancer Dream Team working to translate scientific breakthroughs into new treatment options faster than ever before.

About Stand Up 2 Cancer

Founded in 2008, SU2C has raised more than $180 million for innovative cancer research. Since its inception, SU2C has made grants to seven multi-disciplinary “Dream Teams” of researchers as well as to 26 young innovative scientists who are undertaking potentially high-reward projects to end the reign of cancer as a leading cause of death in the world today.

Eighty-five institutions are currently involved, including Penn Medicine’s Abramson Cancer Center.

The Penn Medicine SU2C Dream Team

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.

The SU2C Dream Team at Penn is actively researching better ways to prevent, diagnose and treat pancreatic cancer. Together, members of the Pancreatic Cancer Dream Team working to translate scientific breakthroughs into new treatment options faster than ever before. Their research focuses on developing tests using advanced imaging technology to understand pancreatic cancer cells and developing new, personalized pancreatic cancer treatments based on their research.

Members of the Pancreatic Cancer SU2C Dream Team at Penn Medicine

Pancreatic cancer researchers at Penn Medicine are at the forefront of developing new, personalized approaches to pancreatic cancer treatment.

These Penn clinicians and researchers are part of the SU2C Pancreatic Cancer Dream Team.

Chi Van Dang, MD, PhD
Professor of Medicine, Hematology/Oncology
Director, Abramson Cancer Center
Director, Abramson Family Cancer Research Institute

Jeffrey A. Drebin, MD, PhD, FACS
John Rhea Barton Professor of Surgery
Chairman, Department of Surgery

Hank Kung, PhD
Professor of Radiology and Pharmacology
Department of Radiology
Perelman School of Medicine

Peter J. O’Dwyer, MBBCh, MD
Professor of Medicine, Hematology/Oncology
Perelman School of Medicine

Watch Stand Up 2 Cancer and Join the Conversation

Watch Stand Up to Cancer on Friday, September 7 at 8 pm ET, and join Penn Medicine on Twitter as we discuss pancreatic cancer and its treatment at Penn Medicine, and how researchers and clinicians on the SU2C Pancreatic Cancer Dream Team are changing the way cancer is treated today.

Cancer Information From a Reliable Source

Thank you for a fantastic 2012. The Focus On Cancer blog is committed to provide people with cancer and their caregivers educated information from a reliable source, the Abramson Cancer Center at Penn Medicine. Please subscribe to our blog to get updates about new cancer treatments at Penn, credible information from cancer experts at Penn, and inspiration from other people with cancer.